The Safety and Efficacy of Hepatic Arterial Infusion Chemotherapy Combined with PD-(L)1 Inhibitors and Molecular Targeted Therapies for the Treatment of Intermediate and Advanced Hepatocellular Carcinoma Unsuitable for Transarterial Chemoembolization

Autor: Tang HH, Zhang MQ, Zhang ZC, Fan C, Jin Y, Wang WD

Publikováno v: Journal of Hepatocellular Carcinoma, Vol Volume 10, Pp 2211-2221 (2023)

Hao-Huan Tang,1,* Ming-Qing Zhang,2,* Zi-Chen Zhang,3,* Chen Fan,1 Yong Jin,2 Wei-Dong Wang1 1Department of Interventional Radiology, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi People’s Hospital, Wuxi Me

Externí odkaz: https://doaj.org/article/64990a4b40044068a5d2aea24dc21a83

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis

Autor: Majem, M, Cobo, M, Isla, D, Marquez-Medina, D, Rodriguez-Abreu, D, Casal-Rubio, J, Moran-Bueno, T, Bernabe-Caro, R, Perez-Parente, D, Ruiz-Gracia, P, Arroyo, MM, Paz-Ares, L

Publikováno v: Journal of Clinical Medicine
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol

Programmed cell death-ligand 1 (PD-L1) has emerged as a potential biomarker for selection of patients more likely to respond to immunotherapy and as a prognostic factor in non-small cell lung cancer (NSCLC). In this network meta-analysis, we aimed to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::0d08ad6c95fe9fda85153cb3c63e834c
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4850

Dynamic Collaborations for the Development of Immune Checkpoint Blockade Agents

Autor: Arisa Djurian, Kota Kodama, Shintaro Sengoku, Yeongjoo Lim, Tomohiro Makino

Publikováno v: Journal of Personalized Medicine
Journal of Personalized Medicine, Vol 11, Iss 460, p 460 (2021)
Volume 11
Issue 6

We studied the overview of drug discovery and development to understand the recent trends and potential success factors of interorganizational collaboration by reviewing 1204 transactions performed until 2019 for 107 anticancer drugs approved by the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12e3f2347ad9945f2f94bb71569d3b39
https://doi.org/10.3390/jpm11060460